Becaplermin (removed 12/2018)

Increased Rate of Mortality Secondary to Malignancy (removed 12/2018)

• An increased risk of mortality secondary to malignancy was observed in patients treated with three or more tubes of becaplermin gel in a post-marketing retrospective cohort study.
• This drug should only be used when the benefits can be expected to outweigh the risks.
• This drug should be used with caution in patients with known malignancy [See Contraindications and WARNINGS]

FDA and Industry Communications

Index to FDA Drug Safety Information

Patient Counseling Information

• REGRANEX

Package Inserts

Becaplermin

Additional Information

• Pub Med - Becaplermin